Evidence map›Paper›PMID 26963616›Full record

ArticlePloS one2016

Wnt5a Regulates the Assembly of Human Adipose Derived Stromal Vascular Fraction-Derived Microvasculatures.

Venkat M Ramakrishnan, Kevin T Tien, Thomas R McKinley, Braden R Bocard, Terry M McCurry, Stuart K Williams, James B Hoying, Nolan L Boyd

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Venkat M RamakrishnanDivision of Cardiovascular Therapeutics, Cardiovascular Innovation Institute, University of Louisville, Louisville, Kentucky, United States of America.
Kevin T TienDivision of Cardiovascular Therapeutics, Cardiovascular Innovation Institute, University of Louisville, Louisville, Kentucky, United States of America.
Thomas R McKinleyDivision of Cardiovascular Therapeutics, Cardiovascular Innovation Institute, University of Louisville, Louisville, Kentucky, United States of America.
Braden R BocardDivision of Cardiovascular Therapeutics, Cardiovascular Innovation Institute, University of Louisville, Louisville, Kentucky, United States of America.
Terry M McCurryDivision of Plastic Surgery, Department of Surgery, University of Louisville, Louisville, Kentucky, United States of America.
Stuart K WilliamsDivision of Cardiovascular Therapeutics, Cardiovascular Innovation Institute, University of Louisville, Louisville, Kentucky, United States of America.
James B HoyingDivision of Cardiovascular Therapeutics, Cardiovascular Innovation Institute, University of Louisville, Louisville, Kentucky, United States of America.
Nolan L BoydDivision of Cardiovascular Therapeutics, Cardiovascular Innovation Institute, University of Louisville, Louisville, Kentucky, United States of America.
University of Louisville · USCardiovascular Innovation Institute · USGeorgetown College · US

Funding

Mechanisms of plasticity and repair after SCIP30GM103507 · NIGMS · UNIVERSITY OF LOUISVILLE · PI WHITTEMORE, SCOTT R · 2012 to 2015
$4.2M
NIGMS NIH HHS P30 GM103507
6 · The paper itself

Abstract

Human adipose-derived stromal vascular fraction (hSVF) cells are an easily accessible, heterogeneous cell system that can spontaneously self-assemble into functional microvasculatures in vivo. However, the mechanisms underlying vascular self-assembly and maturation are poorly understood, therefore we utilized an in vitro model to identify potential in vivo regulatory mechanisms. We utilized passage one (P1) hSVF because of the rapid UEA1+ endothelium (EC) loss at even P2 culture. We exposed hSVF cells to a battery of angiogenesis inhibitors and found that the pan-Wnt inhibitor IWP2 produced the most significant hSVF-EC networking decrease (~25%). To determine which Wnt isoform(s) and receptor(s) may be involved, hSVF was screened by PCR for isoforms associated with angiogenesis, with only WNT5A and its receptor, FZD4, being expressed for all time points observed. Immunocytochemistry confirmed Wnt5a protein expression by hSVF. To see if Wnt5a alone could restore IWP2-induced EC network inhibition, recombinant human Wnt5a (0-150 ng/ml) was added to IWP2-treated cultures. The addition of rhWnt5a significantly increased EC network area and significantly decreased the ratio of total EC network length to EC network area compared to untreated controls. To determine if Wnt5a mediates in vivo microvascular self-assembly, 3D hSVF constructs containing an IgG isotype control, anti-Wnt5a neutralizing antibody or rhWnt5a were implanted subcutaneously for 2w in immune compromised mice. Compared to IgG controls, anti-Wnt5a treatment significantly reduced vessel length density by ~41%, while rhWnt5a significantly increased vessel length density by ~62%. However, anti-Wnt5a or rhWnt5a did not significantly affect the density of segments and nodes, both of which measure vascular complexity. Taken together, this data demonstrates that endogenous Wnt5a produced by hSVF plays a regulatory role in microvascular self-assembly in vivo. These findings also suggest that manipulating Wnt signaling could enhance control of hSVF vascularization in tissue engineering applications.

Indexed as

AdipocytesAnimalsCell DifferentiationCells, CulturedHumansMiceMicrovesselsNeovascularization, PhysiologicProto-Oncogene ProteinsWnt-5a ProteinWnt ProteinsWnt Signaling PathwayProto-Oncogene ProteinsWnt-5a ProteinWNT5A protein, humanWnt Proteins

Identifiers

PMID26963616
PMCPMC4786226
OpenAlexW2296731511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.